Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 May 31:9:899583.
doi: 10.3389/fcvm.2022.899583. eCollection 2022.

Additive Impact of Interleukin 6 and Neuron Specific Enolase for Prognosis in Patients With Out-of-Hospital Cardiac Arrest - Experience From the HAnnover COoling REgistry

Muharrem Akin  1 , Jan-Thorben Sieweke  1 , Vera Garcheva  1 , Carolina Sanchez Martinez  1 , John Adel  1 , Pia Plank  1 , Paris Zandian  1 , Kurt-Wolfram Sühs  2 , Johann Bauersachs  1 , Andreas Schäfer  1
Affiliations

Additive Impact of Interleukin 6 and Neuron Specific Enolase for Prognosis in Patients With Out-of-Hospital Cardiac Arrest - Experience From the HAnnover COoling REgistry

Muharrem Akin et al. Front Cardiovasc Med. .

Abstract

Background: Patients after out-of-hospital cardiac arrest (OHCA) are at increased risk for mortality and poor neurological outcome. We assessed the additive impact of interleukin 6 (IL-6) at admission to neuron-specific enolase (NSE) at day 3 for prognosis of 30-day mortality and long-term neurological outcome in OHCA patients.

Methods: A total of 217 patients from the HAnnover COoling REgistry with return of spontaneous circulation (ROSC) after OHCA and IL-6 measurement immediately after admission during 2017-2020 were included to investigate the prognostic value and importance of IL-6 in addition to NSE obtained on day 3. Poor neurological outcome was defined by cerebral performance category (CPC) ≥ 3 after 6 months.

Results: Patients with poor outcome showed higher IL-6 values (30-day mortality: 2,224 ± 524 ng/l vs 186 ± 15 ng/l, p < 0.001; CPC ≥ 3 at 6 months: 1,440 ± 331 ng/l vs 180 ± 24 ng/l, p < 0.001). IL-6 was an independent predictor of mortality (HR = 1.013/ng/l; 95% CI 1.007-1.019; p < 0.001) and poor neurological outcome (HR = 1.004/ng/l; 95% CI 1.001-1.007; p = 0.036). In ROC-analysis, AUC for IL-6 was 0.98 (95% CI 0.96-0.99) for mortality, but only 0.76 (95% CI 0.68-0.84) for poor neurological outcome. The determined cut-off value for IL-6 was 431 ng/l for mortality (NPV 89.2%). In patients with IL-6 > 431 ng/l, the combination with NSE < 46 μg/l optimally identified those individuals with potential for good neurological outcome (CPC ≤ 2).

Conclusion: Elevated IL-6 levels at admission after ROSC were closely associated with 30-day mortality. The combination of IL-6 and NSE provided clinically important additive information for predict poor neurological outcome at 6 months.

Keywords: interleukin 6; neurological outcome; neuron-specific enolase; out-of-hospital cardiac arrest; prognosis.

PubMed Disclaimer

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Figures

FIGURE 1
FIGURE 1
Distribution of interleukin 6 according to 30-day survival (A) for survivors and non-survivors and according to neurological outcome (B) for patients with good (CPC ≤ 2) and poor outcome (CPC ≥ 3), respectively. For both p was < 0.05.
FIGURE 2
FIGURE 2
Survival proportions of interleukin 6 according to quartiles of HACORE population. p was < 0.0001 in log-rank test.
FIGURE 3
FIGURE 3
ROC curves for NSE and IL-6 for 30-day survival (A) and poor neurological outcome (B). For both p was < 0.001.
FIGURE 4
FIGURE 4
Survival proportions of combined determined cut-off values for mortality for IL-6 and NSE. p was < 0.0001 in log-rank test.
FIGURE 5
FIGURE 5
Neurological outcome according to CPC class in the corresponding groups depending to the determined cut-off values for mortality without patients dying during the first 3 days.
See this image and copyright information in PMC

References

    1. Grasner JT, Herlitz J, Tjelmeland IBM, Wnent J, Masterson S, Lilja G, et al. European resuscitation council guidelines 2021: epidemiology of cardiac arrest in Europe. Resuscitation. (2021) 161:61–79. 10.1016/j.resuscitation.2021.02.007 - DOI - PubMed
    1. Mentzelopoulos SD, Zakynthinos SG. Post-cardiac arrest syndrome: pathological processes, biomarkers and vasopressor support, and potential therapeutic targets. Resuscitation. (2017) 121:A12–4. 10.1016/j.resuscitation.2017.10.013 - DOI - PubMed
    1. Jou C, Shah R, Figueroa A, Patel JK. The role of inflammatory cytokines in cardiac arrest. J Intensive Care Med. (2020) 35:219–24. 10.1177/0885066618817518 - DOI - PubMed
    1. Libby P, Ridker PM. Novel inflammatory markers of coronary risk: theory versus practice. Circulation. (1999) 100:1148–50. 10.1161/01.cir.100.11.1148 - DOI - PubMed
    1. Ruhfus M, Giannakis S, Markus M, Stein A, Hoehn T, Felderhoff-Mueser U, et al. Association of routinely measured proinflammatory biomarkers with abnormal MRI findings in asphyxiated neonates undergoing therapeutic hypothermia. Front Pediatr. (2021) 9:624652. 10.3389/fped.2021.624652 - DOI - PMC - PubMed